Home Healthcare Pharmaceuticals PD-1 And PDL-1 Inhibitor Market

PD-1 And PDL-1 Inhibitor Market Size, Share & Trends Analysis Report By Inhibitors Type (PD-1 Inhibitors, PD-L1 Inhibitors), By Indications (Non-Small Cell Lung Cancer (NSCLC), Melanoma, Hepatocellular Carcinoma (HCC), Colorectal Cancer (CRC), Breast Cancer, Urothelial Carcinoma), By Development Phase (Phase I, Phase II, Phase III, Phase IV) and By Country (U.S., Canada) Forecasts, 2026-2034

Last Updated: July 09, 2026 | Author: Debashree B | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. PD-1 And PDL-1 Inhibitor Market, By Inhibitors Type 2022-2034 (USD MILLION/ Units)
    1. PD-1 Inhibitors
    2. PD-L1 Inhibitors
  2. PD-1 And PDL-1 Inhibitor Market, By Indications 2022-2034 (USD MILLION/ Units)
    1. Non-Small Cell Lung Cancer (NSCLC)
    2. Melanoma
    3. Hepatocellular Carcinoma (HCC)
    4. Colorectal Cancer (CRC)
    5. Breast Cancer
    6. Urothelial Carcinoma
  3. PD-1 And PDL-1 Inhibitor Market, By Development Phase 2022-2034 (USD MILLION/ Units)
    1. Phase I
    2. Phase II
    3. Phase III
    4. Phase IV
  4. Regional PD-1 And PDL-1 Inhibitor Market
    1. North America
      1. North America PD-1 And PDL-1 Inhibitor Market By Inhibitors Type 2022-2034 (USD MILLION/ Units)
        1. PD-1 Inhibitors
        2. PD-L1 Inhibitors
      2. North America PD-1 And PDL-1 Inhibitor Market By Indications 2022-2034 (USD MILLION/ Units)
        1. Non-Small Cell Lung Cancer (NSCLC)
        2. Melanoma
        3. Hepatocellular Carcinoma (HCC)
        4. Colorectal Cancer (CRC)
        5. Breast Cancer
        6. Urothelial Carcinoma
      3. North America PD-1 And PDL-1 Inhibitor Market By Development Phase 2022-2034 (USD MILLION/ Units)
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
      4. U.S.
        1. PD-1 Inhibitors
        2. PD-L1 Inhibitors
        3. Non-Small Cell Lung Cancer (NSCLC)
        4. Melanoma
        5. Hepatocellular Carcinoma (HCC)
        6. Colorectal Cancer (CRC)
        7. Breast Cancer
        8. Urothelial Carcinoma
        9. Phase I
        10. Phase II
        11. Phase III
        12. Phase IV
      5. Canada
        1. PD-1 Inhibitors
        2. PD-L1 Inhibitors
        3. Non-Small Cell Lung Cancer (NSCLC)
        4. Melanoma
        5. Hepatocellular Carcinoma (HCC)
        6. Colorectal Cancer (CRC)
        7. Breast Cancer
        8. Urothelial Carcinoma
        9. Phase I
        10. Phase II
        11. Phase III
        12. Phase IV
    2. Europe
      1. Europe PD-1 And PDL-1 Inhibitor Market By Inhibitors Type 2022-2034 (USD MILLION/ Units)
        1. PD-1 Inhibitors
        2. PD-L1 Inhibitors
      2. Europe PD-1 And PDL-1 Inhibitor Market By Indications 2022-2034 (USD MILLION/ Units)
        1. Non-Small Cell Lung Cancer (NSCLC)
        2. Melanoma
        3. Hepatocellular Carcinoma (HCC)
        4. Colorectal Cancer (CRC)
        5. Breast Cancer
        6. Urothelial Carcinoma
      3. Europe PD-1 And PDL-1 Inhibitor Market By Development Phase 2022-2034 (USD MILLION/ Units)
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
      4. U.K.
        1. PD-1 Inhibitors
        2. PD-L1 Inhibitors
        3. Non-Small Cell Lung Cancer (NSCLC)
        4. Melanoma
        5. Hepatocellular Carcinoma (HCC)
        6. Colorectal Cancer (CRC)
        7. Breast Cancer
        8. Urothelial Carcinoma
        9. Phase I
        10. Phase II
        11. Phase III
        12. Phase IV
      5. Germany
        1. PD-1 Inhibitors
        2. PD-L1 Inhibitors
        3. Non-Small Cell Lung Cancer (NSCLC)
        4. Melanoma
        5. Hepatocellular Carcinoma (HCC)
        6. Colorectal Cancer (CRC)
        7. Breast Cancer
        8. Urothelial Carcinoma
        9. Phase I
        10. Phase II
        11. Phase III
        12. Phase IV
      6. France
        1. PD-1 Inhibitors
        2. PD-L1 Inhibitors
        3. Non-Small Cell Lung Cancer (NSCLC)
        4. Melanoma
        5. Hepatocellular Carcinoma (HCC)
        6. Colorectal Cancer (CRC)
        7. Breast Cancer
        8. Urothelial Carcinoma
        9. Phase I
        10. Phase II
        11. Phase III
        12. Phase IV
      7. Spain
        1. PD-1 Inhibitors
        2. PD-L1 Inhibitors
        3. Non-Small Cell Lung Cancer (NSCLC)
        4. Melanoma
        5. Hepatocellular Carcinoma (HCC)
        6. Colorectal Cancer (CRC)
        7. Breast Cancer
        8. Urothelial Carcinoma
        9. Phase I
        10. Phase II
        11. Phase III
        12. Phase IV
      8. Italy
        1. PD-1 Inhibitors
        2. PD-L1 Inhibitors
        3. Non-Small Cell Lung Cancer (NSCLC)
        4. Melanoma
        5. Hepatocellular Carcinoma (HCC)
        6. Colorectal Cancer (CRC)
        7. Breast Cancer
        8. Urothelial Carcinoma
        9. Phase I
        10. Phase II
        11. Phase III
        12. Phase IV
      9. Russia
        1. PD-1 Inhibitors
        2. PD-L1 Inhibitors
        3. Non-Small Cell Lung Cancer (NSCLC)
        4. Melanoma
        5. Hepatocellular Carcinoma (HCC)
        6. Colorectal Cancer (CRC)
        7. Breast Cancer
        8. Urothelial Carcinoma
        9. Phase I
        10. Phase II
        11. Phase III
        12. Phase IV
      10. Nordic
        1. PD-1 Inhibitors
        2. PD-L1 Inhibitors
        3. Non-Small Cell Lung Cancer (NSCLC)
        4. Melanoma
        5. Hepatocellular Carcinoma (HCC)
        6. Colorectal Cancer (CRC)
        7. Breast Cancer
        8. Urothelial Carcinoma
        9. Phase I
        10. Phase II
        11. Phase III
        12. Phase IV
      11. Benelux
        1. PD-1 Inhibitors
        2. PD-L1 Inhibitors
        3. Non-Small Cell Lung Cancer (NSCLC)
        4. Melanoma
        5. Hepatocellular Carcinoma (HCC)
        6. Colorectal Cancer (CRC)
        7. Breast Cancer
        8. Urothelial Carcinoma
        9. Phase I
        10. Phase II
        11. Phase III
        12. Phase IV
      12. Rest of Europe
        1. PD-1 Inhibitors
        2. PD-L1 Inhibitors
        3. Non-Small Cell Lung Cancer (NSCLC)
        4. Melanoma
        5. Hepatocellular Carcinoma (HCC)
        6. Colorectal Cancer (CRC)
        7. Breast Cancer
        8. Urothelial Carcinoma
        9. Phase I
        10. Phase II
        11. Phase III
        12. Phase IV
    3. APAC
      1. APAC PD-1 And PDL-1 Inhibitor Market By Inhibitors Type 2022-2034 (USD MILLION/ Units)
        1. PD-1 Inhibitors
        2. PD-L1 Inhibitors
      2. APAC PD-1 And PDL-1 Inhibitor Market By Indications 2022-2034 (USD MILLION/ Units)
        1. Non-Small Cell Lung Cancer (NSCLC)
        2. Melanoma
        3. Hepatocellular Carcinoma (HCC)
        4. Colorectal Cancer (CRC)
        5. Breast Cancer
        6. Urothelial Carcinoma
      3. APAC PD-1 And PDL-1 Inhibitor Market By Development Phase 2022-2034 (USD MILLION/ Units)
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
      4. China
        1. PD-1 Inhibitors
        2. PD-L1 Inhibitors
        3. Non-Small Cell Lung Cancer (NSCLC)
        4. Melanoma
        5. Hepatocellular Carcinoma (HCC)
        6. Colorectal Cancer (CRC)
        7. Breast Cancer
        8. Urothelial Carcinoma
        9. Phase I
        10. Phase II
        11. Phase III
        12. Phase IV
      5. Korea
        1. PD-1 Inhibitors
        2. PD-L1 Inhibitors
        3. Non-Small Cell Lung Cancer (NSCLC)
        4. Melanoma
        5. Hepatocellular Carcinoma (HCC)
        6. Colorectal Cancer (CRC)
        7. Breast Cancer
        8. Urothelial Carcinoma
        9. Phase I
        10. Phase II
        11. Phase III
        12. Phase IV
      6. Japan
        1. PD-1 Inhibitors
        2. PD-L1 Inhibitors
        3. Non-Small Cell Lung Cancer (NSCLC)
        4. Melanoma
        5. Hepatocellular Carcinoma (HCC)
        6. Colorectal Cancer (CRC)
        7. Breast Cancer
        8. Urothelial Carcinoma
        9. Phase I
        10. Phase II
        11. Phase III
        12. Phase IV
      7. India
        1. PD-1 Inhibitors
        2. PD-L1 Inhibitors
        3. Non-Small Cell Lung Cancer (NSCLC)
        4. Melanoma
        5. Hepatocellular Carcinoma (HCC)
        6. Colorectal Cancer (CRC)
        7. Breast Cancer
        8. Urothelial Carcinoma
        9. Phase I
        10. Phase II
        11. Phase III
        12. Phase IV
      8. Australia
        1. PD-1 Inhibitors
        2. PD-L1 Inhibitors
        3. Non-Small Cell Lung Cancer (NSCLC)
        4. Melanoma
        5. Hepatocellular Carcinoma (HCC)
        6. Colorectal Cancer (CRC)
        7. Breast Cancer
        8. Urothelial Carcinoma
        9. Phase I
        10. Phase II
        11. Phase III
        12. Phase IV
      9. Taiwan
        1. PD-1 Inhibitors
        2. PD-L1 Inhibitors
        3. Non-Small Cell Lung Cancer (NSCLC)
        4. Melanoma
        5. Hepatocellular Carcinoma (HCC)
        6. Colorectal Cancer (CRC)
        7. Breast Cancer
        8. Urothelial Carcinoma
        9. Phase I
        10. Phase II
        11. Phase III
        12. Phase IV
      10. South East Asia
        1. PD-1 Inhibitors
        2. PD-L1 Inhibitors
        3. Non-Small Cell Lung Cancer (NSCLC)
        4. Melanoma
        5. Hepatocellular Carcinoma (HCC)
        6. Colorectal Cancer (CRC)
        7. Breast Cancer
        8. Urothelial Carcinoma
        9. Phase I
        10. Phase II
        11. Phase III
        12. Phase IV
      11. Rest of Asia-Pacific
        1. PD-1 Inhibitors
        2. PD-L1 Inhibitors
        3. Non-Small Cell Lung Cancer (NSCLC)
        4. Melanoma
        5. Hepatocellular Carcinoma (HCC)
        6. Colorectal Cancer (CRC)
        7. Breast Cancer
        8. Urothelial Carcinoma
        9. Phase I
        10. Phase II
        11. Phase III
        12. Phase IV
    4. Middle East and Africa
      1. Middle East and Africa PD-1 And PDL-1 Inhibitor Market By Inhibitors Type 2022-2034 (USD MILLION/ Units)
        1. PD-1 Inhibitors
        2. PD-L1 Inhibitors
      2. Middle East and Africa PD-1 And PDL-1 Inhibitor Market By Indications 2022-2034 (USD MILLION/ Units)
        1. Non-Small Cell Lung Cancer (NSCLC)
        2. Melanoma
        3. Hepatocellular Carcinoma (HCC)
        4. Colorectal Cancer (CRC)
        5. Breast Cancer
        6. Urothelial Carcinoma
      3. Middle East and Africa PD-1 And PDL-1 Inhibitor Market By Development Phase 2022-2034 (USD MILLION/ Units)
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
      4. UAE
        1. PD-1 Inhibitors
        2. PD-L1 Inhibitors
        3. Non-Small Cell Lung Cancer (NSCLC)
        4. Melanoma
        5. Hepatocellular Carcinoma (HCC)
        6. Colorectal Cancer (CRC)
        7. Breast Cancer
        8. Urothelial Carcinoma
        9. Phase I
        10. Phase II
        11. Phase III
        12. Phase IV
      5. Turkey
        1. PD-1 Inhibitors
        2. PD-L1 Inhibitors
        3. Non-Small Cell Lung Cancer (NSCLC)
        4. Melanoma
        5. Hepatocellular Carcinoma (HCC)
        6. Colorectal Cancer (CRC)
        7. Breast Cancer
        8. Urothelial Carcinoma
        9. Phase I
        10. Phase II
        11. Phase III
        12. Phase IV
      6. Saudi Arabia
        1. PD-1 Inhibitors
        2. PD-L1 Inhibitors
        3. Non-Small Cell Lung Cancer (NSCLC)
        4. Melanoma
        5. Hepatocellular Carcinoma (HCC)
        6. Colorectal Cancer (CRC)
        7. Breast Cancer
        8. Urothelial Carcinoma
        9. Phase I
        10. Phase II
        11. Phase III
        12. Phase IV
      7. South Africa
        1. PD-1 Inhibitors
        2. PD-L1 Inhibitors
        3. Non-Small Cell Lung Cancer (NSCLC)
        4. Melanoma
        5. Hepatocellular Carcinoma (HCC)
        6. Colorectal Cancer (CRC)
        7. Breast Cancer
        8. Urothelial Carcinoma
        9. Phase I
        10. Phase II
        11. Phase III
        12. Phase IV
      8. Egypt
        1. PD-1 Inhibitors
        2. PD-L1 Inhibitors
        3. Non-Small Cell Lung Cancer (NSCLC)
        4. Melanoma
        5. Hepatocellular Carcinoma (HCC)
        6. Colorectal Cancer (CRC)
        7. Breast Cancer
        8. Urothelial Carcinoma
        9. Phase I
        10. Phase II
        11. Phase III
        12. Phase IV
      9. Nigeria
        1. PD-1 Inhibitors
        2. PD-L1 Inhibitors
        3. Non-Small Cell Lung Cancer (NSCLC)
        4. Melanoma
        5. Hepatocellular Carcinoma (HCC)
        6. Colorectal Cancer (CRC)
        7. Breast Cancer
        8. Urothelial Carcinoma
        9. Phase I
        10. Phase II
        11. Phase III
        12. Phase IV
      10. Rest of MEA
        1. PD-1 Inhibitors
        2. PD-L1 Inhibitors
        3. Non-Small Cell Lung Cancer (NSCLC)
        4. Melanoma
        5. Hepatocellular Carcinoma (HCC)
        6. Colorectal Cancer (CRC)
        7. Breast Cancer
        8. Urothelial Carcinoma
        9. Phase I
        10. Phase II
        11. Phase III
        12. Phase IV
    5. LATAM
      1. LATAM PD-1 And PDL-1 Inhibitor Market By Inhibitors Type 2022-2034 (USD MILLION/ Units)
        1. PD-1 Inhibitors
        2. PD-L1 Inhibitors
      2. LATAM PD-1 And PDL-1 Inhibitor Market By Indications 2022-2034 (USD MILLION/ Units)
        1. Non-Small Cell Lung Cancer (NSCLC)
        2. Melanoma
        3. Hepatocellular Carcinoma (HCC)
        4. Colorectal Cancer (CRC)
        5. Breast Cancer
        6. Urothelial Carcinoma
      3. LATAM PD-1 And PDL-1 Inhibitor Market By Development Phase 2022-2034 (USD MILLION/ Units)
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
      4. Brazil
        1. PD-1 Inhibitors
        2. PD-L1 Inhibitors
        3. Non-Small Cell Lung Cancer (NSCLC)
        4. Melanoma
        5. Hepatocellular Carcinoma (HCC)
        6. Colorectal Cancer (CRC)
        7. Breast Cancer
        8. Urothelial Carcinoma
        9. Phase I
        10. Phase II
        11. Phase III
        12. Phase IV
      5. Mexico
        1. PD-1 Inhibitors
        2. PD-L1 Inhibitors
        3. Non-Small Cell Lung Cancer (NSCLC)
        4. Melanoma
        5. Hepatocellular Carcinoma (HCC)
        6. Colorectal Cancer (CRC)
        7. Breast Cancer
        8. Urothelial Carcinoma
        9. Phase I
        10. Phase II
        11. Phase III
        12. Phase IV
      6. Argentina
        1. PD-1 Inhibitors
        2. PD-L1 Inhibitors
        3. Non-Small Cell Lung Cancer (NSCLC)
        4. Melanoma
        5. Hepatocellular Carcinoma (HCC)
        6. Colorectal Cancer (CRC)
        7. Breast Cancer
        8. Urothelial Carcinoma
        9. Phase I
        10. Phase II
        11. Phase III
        12. Phase IV
      7. Chile
        1. PD-1 Inhibitors
        2. PD-L1 Inhibitors
        3. Non-Small Cell Lung Cancer (NSCLC)
        4. Melanoma
        5. Hepatocellular Carcinoma (HCC)
        6. Colorectal Cancer (CRC)
        7. Breast Cancer
        8. Urothelial Carcinoma
        9. Phase I
        10. Phase II
        11. Phase III
        12. Phase IV
      8. Colombia
        1. PD-1 Inhibitors
        2. PD-L1 Inhibitors
        3. Non-Small Cell Lung Cancer (NSCLC)
        4. Melanoma
        5. Hepatocellular Carcinoma (HCC)
        6. Colorectal Cancer (CRC)
        7. Breast Cancer
        8. Urothelial Carcinoma
        9. Phase I
        10. Phase II
        11. Phase III
        12. Phase IV
      9. Rest of LATAM
        1. PD-1 Inhibitors
        2. PD-L1 Inhibitors
        3. Non-Small Cell Lung Cancer (NSCLC)
        4. Melanoma
        5. Hepatocellular Carcinoma (HCC)
        6. Colorectal Cancer (CRC)
        7. Breast Cancer
        8. Urothelial Carcinoma
        9. Phase I
        10. Phase II
        11. Phase III
        12. Phase IV
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.